Literature DB >> 20489166

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.

James P Corsetti1, Dan Ryan, David L Rainwater, Arthur J Moss, Wojciech Zareba, Charles E Sparks.   

Abstract

OBJECTIVE: To investigate the roles of inflammation and a cholesteryl ester transfer protein (CETP) polymorphism potentially related to recent findings demonstrating coronary risk with increasing high-density lipoprotein cholesterol (HDL-C) level. METHODS AND
RESULTS: A novel graphical exploratory data analysis tool allowed the examination of coronary risk in postinfarction patients relating to HDL-C and C-reactive protein levels. Results demonstrated a high-risk subgroup, defined by high HDL-C and C-reactive protein levels, exhibiting larger HDL particles and lower lipoprotein-associated phospholipaseA(2) levels than lower-risk patients. Subgroup CETP-associated risk was probed using a functional CETP polymorphism (TaqIB, rs708272). In the high-risk subgroup, multivariable modeling revealed greater risk for B2 allele carriers (less CETP activity) versus B1 homozygotes (hazard ratio, 2.41; 95% CI, 1.04 to 5.60; P=0.04). Within the high-risk subgroup, B2 allele carriers had higher serum amyloid A levels than B1 homozygotes. Evidence also demonstrates that CETP genotypic differences in HDL subfraction distributions regarding non-HDL-C and lipoprotein-associated phospholipaseA(2) may potentially relate to impaired HDL remodeling.
CONCLUSIONS: Postinfarction patients with high HDL-C and C-reactive protein levels demonstrate increased risk for recurrent events. Future studies should aim at characterizing altered HDL particles from such patients and at elucidating the mechanistic details related to inflammation and HDL particle remodeling. Such patients should be considered in drug trials involving an increase in HDL-C level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489166      PMCID: PMC3051187          DOI: 10.1161/ATVBAHA.110.207977

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  34 in total

Review 1.  Electrophoretic separation of LDL and HDL subclasses.

Authors:  D L Rainwater
Journal:  Methods Mol Biol       Date:  1998

2.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

3.  Inflammation reduces HDL protection against primary cardiac risk.

Authors:  James P Corsetti; Ron T Gansevoort; Charles E Sparks; Robin P F Dullaart
Journal:  Eur J Clin Invest       Date:  2010-04-14       Impact factor: 4.686

Review 4.  Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.

Authors:  Alexander Thompson; Emanuele Di Angelantonio; Nadeem Sarwar; Sebhat Erqou; Danish Saleheen; Robin P F Dullaart; Bernard Keavney; Zheng Ye; John Danesh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

Review 5.  The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.

Authors:  Constantinos C Tellis; Alexandros D Tselepis
Journal:  Biochim Biophys Acta       Date:  2009-05

6.  High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants.

Authors:  Bernadette A C van Acker; Gert-Jan Botma; Aeilko H Zwinderman; Jan Albert Kuivenhoven; Geesje M Dallinga-Thie; Eric J G Sijbrands; Jolanda M A Boer; Jacob C Seidell; J Wouter Jukema; John J P Kastelein; Hans Jansen; Adrie J M Verhoeven
Journal:  Atherosclerosis       Date:  2007-12-27       Impact factor: 5.162

Review 7.  Obesity, inflammation, and atherosclerosis.

Authors:  Viviane Z Rocha; Peter Libby
Journal:  Nat Rev Cardiol       Date:  2009-04-28       Impact factor: 32.419

Review 8.  Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease.

Authors:  S Matthijs Boekholdt; John F Thompson
Journal:  J Lipid Res       Date:  2003-03-16       Impact factor: 5.922

9.  The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis.

Authors:  David Masson; Xian-Cheng Jiang; Laurent Lagrost; Alan R Tall
Journal:  J Lipid Res       Date:  2008-11-20       Impact factor: 5.922

10.  Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.

Authors:  Reecha Sofat; Aroon D Hingorani; Liam Smeeth; Steve E Humphries; Philippa J Talmud; Jackie Cooper; Tina Shah; Manjinder S Sandhu; Sally L Ricketts; S Matthijs Boekholdt; Nicholas Wareham; Kay Tee Khaw; Meena Kumari; Mika Kivimaki; Michael Marmot; Folkert W Asselbergs; Pim van der Harst; Robin P F Dullaart; Gerjan Navis; Dirk J van Veldhuisen; Wiek H Van Gilst; John F Thompson; Pamela McCaskie; Lyle J Palmer; Marcello Arca; Fabiana Quagliarini; Carlo Gaudio; François Cambien; Viviane Nicaud; Odette Poirer; Vilmundur Gudnason; Aaron Isaacs; Jacqueline C M Witteman; Cornelia M van Duijn; Michael Pencina; Ramachandran S Vasan; Ralph B D'Agostino; Jose Ordovas; Tricia Y Li; Sakari Kakko; Heikki Kauma; Markku J Savolainen; Y Antero Kesäniemi; Anton Sandhofer; Bernhard Paulweber; Jose V Sorli; Akimoto Goto; Shinji Yokoyama; Kenji Okumura; Benjamin D Horne; Chris Packard; Dilys Freeman; Ian Ford; Naveed Sattar; Valerie McCormack; Debbie A Lawlor; Shah Ebrahim; George Davey Smith; John J P Kastelein; John Deanfield; Juan P Casas
Journal:  Circulation       Date:  2009-12-21       Impact factor: 29.690

View more
  19 in total

1.  A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.

Authors:  Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

Review 2.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

3.  Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women.

Authors:  Genevieve A Woodard; Maria M Brooks; Emma Barinas-Mitchell; Rachel H Mackey; Karen A Matthews; Kim Sutton-Tyrrell
Journal:  Menopause       Date:  2011-04       Impact factor: 2.953

Review 4.  HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Nat Rev Cardiol       Date:  2011-02-08       Impact factor: 32.419

5.  ABCA1, ABCG1, and Cholesterol Homeostasis.

Authors:  Xiao-Hua Yu; Chao-Ke Tang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

Authors:  Zahi A Fayad; Venkatesh Mani; Mark Woodward; David Kallend; Markus Abt; Tracy Burgess; Valentin Fuster; Christie M Ballantyne; Evan A Stein; Jean-Claude Tardif; James H F Rudd; Michael E Farkouh; Ahmed Tawakol
Journal:  Lancet       Date:  2011-09-09       Impact factor: 79.321

7.  Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation.

Authors:  Nhat-Tu Le; James P Corsetti; Janet L Dehoff-Sparks; Charles E Sparks; Keigi Fujiwara; Jun-Ichi Abe
Journal:  Int J Inflam       Date:  2012-09-06

8.  Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein.

Authors:  James P Corsetti; Stephan J L Bakker; Charles E Sparks; Robin P F Dullaart
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

9.  Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response.

Authors:  Hima Bindu G; Veena S Rao; Vijay V Kakkar
Journal:  Cholesterol       Date:  2010-11-25

10.  Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.

Authors:  James P Corsetti; Peter Salzman; Dan Ryan; Arthur J Moss; Wojciech Zareba; Charles E Sparks
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.